Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Score d'opportunité
Pourquoi ce score ?
Opportunité
65 / 100
Complexité
20 / 100
Facteurs de risque
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Strong opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Supply of Denosumab (ATC M05BX04) pharmaceuticals.
- Conclude non-exclusive discount agreements with AOK Bayern under §130a Abs. 8 SGB V.
Afficher le résumé complet
Open-house model for non-exclusive discount agreements on Denosumab (ATC M05BX04) with AOK Bayern. All qualifying pharmaceutical companies can join on identical terms. Contract runs from 01.11.2024 to 31.10.2026, with possible earlier termination if a competitive discount contract comes into effect. No selection or award criteria – everyone who meets eligibility gets a contract.
Risques
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Submission deadline in 7 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Tenderer must be a pharmaceutical company (pharmazeutischer Unternehmer).
Administrative
- Submit signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
- Submit signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
Les exigences peuvent être incomplètes.
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04
Non-exclusive discount agreements for Denosumab. All interested pharmaceutical companies that meet the eligibility criteria can sign identical contracts. Contracts can be concluded anytime until 05.09.2026. Place of performance: Bayern (DE212).
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung
Afficher les données TED originales
Description TED originale
Siehe kurze Beschreibung
Détails de la procédure
- Date de publication
- 16 Sep 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 557186-2024
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
65 / 100
Complexité
20 / 100
Facteurs de risque
Open-house contracts automatically cease if a competitive discount contract for Denosumab is concluded at federal or st...
Incorrect submission (e.g., missing signatures, not meeting format requirements) may delay contract start.
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications